

Pain Therapeutics

Drugs, Markets & Companies

By

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

September 2017

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training and received graduate training in both Europe and US. He has held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. During his active neurosurgical career, Prof. Jain was involved in the management of pain. He has been working in the biotechnology/biopharmaceuticals industry for several years and currently is the CEO at Jain PharmaBiotech.

Prof. Jain is an Associate Editor of MedLink Neurology, an electronic encyclopedia of neurology published by Medlink Corporation (San Diego, California) where he is also the author in charge of writing and yearly update of 160 articles including those on treatment of pain.

Prof. Jain's 470 publications including 28 books (5 as editor + 23 as author) and 50 special reports which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. He has also written a textbook of gene therapy, which is the first book on this subject to be translated into the Chinese language. A book on gene therapy companies was published in 2000 by John Wiley & Sons and the updated version has been incorporated into a report on Gene Therapy published by Jain PharmaBiotech in 2014. Prof. Jain has edited "Drug Delivery Systems" (Humana/Springer 2008, 2nd ed 2014) and "Drug Delivery to the Central Nervous System" (Humana/Springer 2010). His other recent books include "Handbook of Nanomedicine" (Springer/Humana 2008; Chinese edition, Peking University Press 2011, 2nd ed Springer 2012, 3rd ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer, 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition, Chemical Industry Press 2016, 2nd ed Springer, 2017), "Handbook of Neuroprotection" (Springer 2011), "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer, January 2014). He has edited "Applied Neurogenomics" (Springer 2015).

The pain report is an update with inclusion of commercial information in an earlier publication titled "Pain Therapeutics: A strategic re-evaluation" published by Reuter's Business Insight/Datamonitor UK in 2000. Other reports written by Prof. Jain in the past have been published by PJB Publications, D & MD, Informa, and Decision Resources Inc. This is one of the in-house publications of Jain PharmaBiotech that are constantly updated.

September 2017
Copyright ©2017 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	18
1. Basic Aspects of Pain	20
Introduction	20
Historical aspects of pain	20
Pain definitions	22
A glossary of terms relevant to pain	23
Pain classification and description	23
Neuropathic pain	24
<i>Refractory neuropathic pain</i>	<i>25</i>
<i>Classification of neuropathic pain according to levels</i>	<i>25</i>
Cancer pain	26
<i>Bone pain in cancer</i>	<i>28</i>
Complex regional pain syndrome	29
Mechanisms of pain	29
Pain pathways	29
<i>Role of nociceptors in pain transmission</i>	<i>31</i>
Gate control and neuromatrix theories of pain	31
Pain mediators	32
Modulation of pain by pictures associated with social contacts	33
Modulation of pain by emotions	33
Role of the sympathetic nervous system in pain	33
Visceral pain	33
<i>Pathomechanism of visceral pain</i>	<i>34</i>
Pathomechanism of neuropathic pain	34
<i>Role of intact nerve fibers in neuropathic pain</i>	<i>34</i>
<i>Chemokines as mediators of neuropathic pain</i>	<i>34</i>
<i>Chemotherapy-induced neuropathic pain</i>	<i>35</i>
<i>CNS innate immunity and neuropathic pain</i>	<i>35</i>
<i>Cytokines as mediators of neuropathic pain</i>	<i>35</i>
<i>Free radicals in generation of neuropathic pain</i>	<i>36</i>
<i>GABA deficiency in neuropathic pain</i>	<i>36</i>
<i>Genetic basis of neuropathic pain</i>	<i>36</i>
<i>Gene expression changes in neuropathic pain</i>	<i>36</i>
<i>Glial activation and neuropathic pain</i>	<i>37</i>
<i>Immune cell-derived opioids and neuropathic pain</i>	<i>38</i>
<i>Spinal leptin and neuropathic pain</i>	<i>38</i>
<i>Tetrahydrobiopterin regulates neuropathic pain sensitivity</i>	<i>38</i>
Pathomechanism of migraine	38
Role of the immune system in pain	39
Pain and itch	40
<i>Pathomechanism of itch</i>	<i>40</i>
<i>Clinical aspects of itch</i>	<i>41</i>
Molecular pathophysiology of pain	41
Role of ion channels in pain	41
<i>Acid-sensing ion channels</i>	<i>42</i>
<i>Calcium channels in pain</i>	<i>42</i>
<i>P2X3 ion channels</i>	<i>43</i>
<i>Potassium ion channels</i>	<i>43</i>
<i>Sodium ion channels in pain</i>	<i>43</i>
<i>TRP ion channels in pain</i>	<i>44</i>
Genetic basis of pain	45
<i>Alternative RNA splicing and pain</i>	<i>46</i>
<i>Study of genes in pain</i>	<i>47</i>
<i>Pain as a channelopathy</i>	<i>47</i>
Pain in the brain	47
<i>Effect of chronic pain on opioid receptors in the brain</i>	<i>48</i>
<i>Neuropathic pain-induced morphological changes in the brain</i>	<i>48</i>
Change from acute to chronic pain	48
<i>Acute versus chronic pain</i>	<i>49</i>
<i>Descending facilitatory modulation of pain</i>	<i>49</i>
<i>Development of chronic pain following severe accidental injury</i>	<i>49</i>
<i>Pain and transcriptional repressor DREAM</i>	<i>50</i>
<i>Role of neuronal plasticity in pain</i>	<i>50</i>
<i>Role of epigenetics in development of chronic pain</i>	<i>51</i>
<i>Concluding remarks on evolution of acute pain into chronic pain</i>	<i>51</i>
Neurochemistry of pain	51
<i>Molecular elements of pain in the peripheral nervous system</i>	<i>51</i>

<i>Molecular elements of pain in the central nervous system</i>	52
<i>Opioid receptors</i>	52
<i>Role of AMPA receptors in chronic pain</i>	53
<i>Kinins</i>	53
<i>Serotonin</i>	54
<i>Substance P</i>	54
<i>Excitatory amino acids</i>	54
<i>Role of nitric oxide in pain</i>	54
<i>Prostaglandins</i>	55
<i>Endocannabinoids</i>	56
<i>Protein kinase C</i>	56
<i>Adenosine and adenosine receptors</i>	56
<i>Vitamin D and pain</i>	57
<i>Vanilloid receptor</i>	57
<i>TRPA₁ and TRPV₁ receptors</i>	57
<i>Endothelin-B receptors</i>	59
<i>Nerve growth factor and pain</i>	59
<i>Adrenomedullin as a pain-related peptide</i>	59
Biomarkers of pain	60
<i>Biomarkers of visceral pain</i>	60
2. Assessment of Pain and Analgesics	62
Introduction	62
Animal models of pain	62
An overview	62
Selection of animal species as models for pain	62
Types of noxious stimuli	63
Animal models of neuropathic pain	63
Animal models of arthritis	63
Animal models of peripheral neuropathy	64
Limitations of current pain models	64
NeuroDigm GEL Model™ of neuropathic pain	65
Ethical issues concerning animal pain models	65
Medical evaluation of pain	66
Chronic pain as a manifestation of various diseases	66
Assessment of pain patients	66
Medical examination	66
Measurement of pain	67
Quality of pain intensity assessment in clinical research studies	68
Quantitative sensory testing	69
Pain measurement tools for neonates and children	69
Quantitative sensory testing	70
Microneurographic recordings	70
Psychological assessment of pain	71
Testing for in vivo pain processing	71
Brain imaging in pain	71
<i>fMRI for study of pain</i>	71
<i>PET for study of pain</i>	71
<i>PET correlated with fMRI and evoked potentials</i>	72
Patient outcomes and quality of life during treatment for chronic pain	72
Collection and analysis of data on pain patients	73
Evaluation of analgesics in humans	73
Early phase clinical trials of analgesics in humans	73
Design of clinical trials for pain	74
Assessment of neuropathic pain	75
Transdermal electrical stimulation for study of chronic pain	75
Placebo effect in pain	76
Role of electronic pain recording in determination of the placebo effect	76
Outcome measures for chronic pain trials	76
Pain, pain therapies and cognitive function	77
3. Pharmacotherapy of Pain	78
Introduction	78
Mechanism of action of currently used pain medications	78
Non-steroidal antiinflammatory drugs	79
COX-2 inhibitors	79
<i>Celecoxib</i>	80
<i>Metamizole</i>	81
<i>Nimesulide</i>	81
<i>Rofecoxib</i>	81
<i>Valdecoxib</i>	82

<i>Lumiracoxib</i>	82
<i>Side effects of COX inhibitors</i>	82
<i>Innovative COX-2 inhibitors in development</i>	84
Acetaminophen.....	85
Antioxidants as analgesics.....	85
Opiates and opioids	85
Morphine	86
Codeine	86
Tramadol.....	87
Innovations in opioid therapy	87
<i>Oral transmucosal fentanyl</i>	88
<i>Use of opioids for chronic non-cancer pain</i>	88
Opioid receptor modulation for visceral pain	88
Opiorphin.....	89
N-methyl-D-aspartate receptor antagonists	89
Ketamine	89
CNS 5161	90
Triptans for treatment of non-migrainous pain.....	90
Capsaicin	90
NGX-4010.....	91
Local anesthetics	91
Topical application	91
Nerve blocks	91
<i>Injection of local anesthetics for analgesia</i>	92
<i>Ultrasound-guided nerve blocks</i>	92
Topical salicylates for the treatment of pain.....	92
Topical rubefacients for acute and chronic pain in adults	92
Adjunctive analgesics	93
Antidepressants.....	93
<i>Mechanism of analgesic action of antidepressants</i>	94
Antiepileptic drugs	95
<i>Mechanism of action of antiepileptic drugs in neuropathic pain</i>	96
<i>Carbamazepine</i>	96
<i>Gabapentin</i>	97
<i>Lamotrigine</i>	97
<i>Phenytoin</i>	98
<i>Pregabalin</i>	98
<i>Topiramate</i>	99
<i>Valproic acid</i>	99
<i>Other antiepileptic drugs</i>	99
Clonidine.....	100
Baclofen.....	100
Corticosteroids	101
Calcitonin.....	101
Bisphosphonates	101
Botulinum toxins	102
Analgesic effect of botulinum toxin A.....	102
Engineered botulinum toxin.....	102
Analgesics from traditional medical systems	103
Herbs and other plants	103
Analgesics derived from cobra toxin	104

4. Management of Pain	106
Introduction	106
Sites for pain management.....	106
Self-medication at home.....	106
Physicians' offices	106
Major hospitals	106
Pain centers	107
Non-pharmacological approaches to pain	107
Alternative medicine.....	107
<i>Acupuncture</i>	108
<i>Aromatherapy</i>	108
<i>Self-Controlled Energo Neuro Adaptive Regulation</i>	109
Behavioral therapy.....	109
<i>Cognition and pain</i>	109
<i>Control over brain activation and pain by using functional MRI</i>	109
<i>Mindfulness meditation for relief of chronic pain</i>	110
<i>Thermal-grill illusion</i>	110
<i>Virtual reality therapy</i>	110
Local application of heat	110

Transcutaneous nerve stimulation.....	111
Non-invasive brain stimulation techniques for chronic pain.....	111
<i>Transcranial magnetic stimulation</i>	111
<i>Cranial electrotherapy stimulation</i>	112
Neurosurgery for pain relief.....	112
<i>Ablative procedures on the nervous system</i>	112
<i>Procedures on peripheral, spinal and cranial nerves</i>	112
<i>Vagal nerve stimulation for control of pain</i>	113
<i>Neuromodulation</i>	113
<i>Spinal cord stimulation</i>	114
<i>Brain stimulation</i>	115
<i>Implantation of drug delivery devices</i>	116
Management of special types of pain.....	116
Acute pain.....	116
<i>Management of acute renal colic: NSAIDs vs. opioids</i>	116
<i>Combination of opioids and NSAIDs for acute pain</i>	116
<i>Reasons for inadequate management of acute pain</i>	117
Perioperative pain management.....	117
<i>Devices for delivery of analgesics in the postoperative period</i>	118
<i>Drug combination for perioperative pain</i>	119
<i>Gabapentin for reduction of postoperative pain</i>	119
<i>Ketamine for perioperative pain</i>	119
<i>Opioids for perioperative pain</i>	120
<i>Perioperative pain in neurosurgery</i>	120
<i>Prolonged duration local anesthesia</i>	121
<i>Concluding remarks on the management of postoperative pain</i>	121
Pain in the intensive care unit.....	121
Pain associated with sports and exercise.....	122
Pain associated with trauma.....	122
Chronic abdominal pain.....	123
Functional somatic syndromes.....	123
Fibromyalgia syndrome.....	124
<i>Pathomechanism of FMS</i>	124
<i>Management of FMS</i>	125
<i>Non-pharmacological therapies for FMS</i>	125
<i>Pharmacotherapy of FMS</i>	125
<i>Concluding remarks on management of FMS</i>	127
Erythromelalgia.....	127
Irritable bowel syndrome.....	127
<i>Opioids for IBS</i>	128
<i>Tricyclic antidepressants for IBS</i>	129
<i>Serotonin-modulating drugs for IBS</i>	129
Musculoskeletal pain.....	129
Myofascial pain syndrome.....	129
<i>Non-pharmacological methods of treatment of MPS</i>	130
<i>Pharmacotherapy of MPS</i>	130
Osteoarthritis.....	131
<i>Pain aggravates osteoarthritis by crosstalk between CNS and the joint</i>	132
<i>Management of osteoarthritis</i>	132
Rheumatoid arthritis.....	133
<i>Management of pain in rheumatoid arthritis</i>	134
<i>Disease modifying therapies in rheumatoid arthritis</i>	134
<i>Resurgence of interest in gold-based treatments for RA</i>	136
Backache and sciatica.....	136
<i>Lumbar disc disease and sciatica</i>	137
<i>Management of back pain with analgesics</i>	137
<i>Miscellaneous medical therapies for backache and sciatica</i>	138
Neck pain.....	139
Chronic pelvic pain.....	139
<i>Prostatitis</i>	140
Cancer pain.....	140
<i>Adjuvant drugs for cancer pain</i>	140
<i>Alternative non-pharmacological methods</i>	141
<i>Anesthetic techniques</i>	141
<i>Management of bone pain in cancer</i>	141
<i>Non-opioid analgesics for cancer pain</i>	142
<i>Opioid treatment of cancer pain</i>	142
<i>Opioid breakthrough pains</i>	143
<i>Opioid-induced enhancement of cancer growth and its prevention</i>	144
<i>Opioids delivery methods for cancer pain</i>	144
<i>Opioid administration through implanted drug delivery devices</i>	145

<i>Radiation therapy</i>	145
<i>Surgical methods of cancer pain relief</i>	145
<i>Conclusions regarding management of cancer pain</i>	145
Chronic non-malignant pain	146
Headache.....	146
<i>Cluster headache</i>	147
<i>Chronic daily headache</i>	147
<i>Indomethacin-responsive headache</i>	148
<i>Occipital neuralgia</i>	148
<i>Paroxysmal hemicrania</i>	149
<i>Tension headache</i>	149
Migraine	150
<i>Management of acute migraine</i>	150
<i>Pediatric migraine</i>	154
<i>Status migrainosus</i>	154
<i>Migraine prophylaxis</i>	155
<i>Non-pharmacological approaches to migraine</i>	156
Trigeminal neuralgia.....	158
Dental pain	158
Neuropathic pain.....	158
<i>Pathogenesis of neuropathic pain</i>	159
<i>Chronobiology of neuropathic pain as guide to therapy</i>	159
<i>Management of neuropathic pain based on mechanism</i>	160
<i>Guidelines for the management of neuropathic pain</i>	160
<i>Pharmacotherapy of neuropathic pain</i>	161
<i>Evidence-based management of neuropathic pain</i>	162
Management of central neuropathic pain.....	163
<i>Neurosurgical approaches to central neuropathic pain</i>	163
<i>Management of neuropathic pain in syringomyelia</i>	164
<i>Neuropathic pain associated with spinal cord injury</i>	164
Peripheral neuropathic pain	165
<i>Truncal neuropathic pain</i>	165
<i>Management of postsurgical peripheral neuropathic pain</i>	165
<i>Management of chemotherapy-induced pain</i>	165
<i>Morton's neuroma</i>	166
<i>Management of peripheral diabetic neuropathy</i>	166
<i>Postherpetic neuralgia</i>	168
<i>Complex regional pain syndrome</i>	170
<i>An algorithm for the management of peripheral neuropathic pain</i>	172
Phantom limb pain	172
<i>Pathomechanism of phantom limb pain</i>	172
<i>Management of phantom limb pain</i>	173
Pain and depression	175
<i>Neurochemical link between pain and depression</i>	176
<i>Management of chronic pain and depression</i>	176
Miscellaneous painful conditions.....	177
<i>Burning mouth syndrome</i>	177
<i>Chronic unstable angina</i>	177
<i>Mastalgia</i>	177
<i>Ophthalmic pain</i>	178
<i>Pain in Parkinson's disease</i>	178
Pain in sickle cell disease	179
Management of chronic unexplained pain.....	179
Management of itching	180
<i>Topical applications for itching</i>	180
<i>Systemic therapies for itching</i>	181
<i>Non-pharmacological therapies for itch</i>	182
Management of pain in special population groups	182
Racial and ethnic differences in pain management	182
Pain in neonates	182
Management of pain in children	183
<i>Misuse of codeine in children</i>	184
Management of pain in the elderly	184
Management of pain in women	185
<i>Reasons for increased pain perception in women</i>	186
<i>Chronic pelvic pain in women</i>	186
<i>Gender differences in response to analgesics</i>	186
<i>Considerations for pain management in women</i>	187
Management of pain in neurologically handicapped persons	187
Management of pain in the cognitively impaired elderly people	187
Management of pain in brain-damaged minimally conscious patients.....	188

Management of pain in the terminally ill	188
Problems in the management of pain	189
Inadequate pain management	189
Problems with use of opioids	190
<i>Guideline for use of opioids</i>	190
<i>Opioid regulations</i>	191
<i>Opioids alternatives</i>	192
Excessive prescription of gabapentinoids	192
<i>Problems with use of gabapentinoids</i>	192
Suggestions for improvement of pain management by healthcare providers	193
<i>Management of neuropathic pain refractory to first line treatment</i>	195
<i>Multidisciplinary approaches to pain management</i>	195
<i>Pain as the fifth vital sign</i>	195
<i>Reassessment of management of chronic pain</i>	195
5. Drug Delivery for Pain	198
Introduction	198
Intra-articular injection for relief of joint pain.....	199
Delivery of analgesics to peripheral nerves	199
Controlled release drug delivery for pain.....	200
Accelerating the effect of subcutaneous morphine	200
Controlled drug delivery at site of pain	200
Oral extended release opioids.....	201
<i>Extended release oral morphine</i>	201
<i>Controlled release oxycodone</i>	201
<i>Extended release oxymorphone</i>	201
<i>Oral extended release tramadol</i>	202
Extended release gabapentin.....	202
Use of nanotechnology for drug delivery for pain	203
Non-injection methods of delivery of analgesics.....	203
Topical applications for pain	204
<i>Topical local anesthetics</i>	204
<i>Topical NSAIDs</i>	204
<i>Topical and transdermal diclofenac</i>	205
<i>Topical application for postoperative pain</i>	205
Needle-free drug delivery for pain	206
<i>Glide SDI® solid dose injector</i>	206
<i>SUMAVEL™ DosePro™ needle-less injection</i>	206
Transdermal drug delivery for pain.....	206
<i>Relief of pain associated with minor medical procedures</i>	206
<i>Transdermal fentanyl</i>	207
<i>Transdermal ketoprofen</i>	208
<i>Transdermal nitroglycerine as an adjuvant to opioids</i>	209
<i>Transdermal buprenorphine</i>	209
<i>Transdermal trans-capsaicin</i>	209
<i>Powder Injection Systems</i>	209
Intranasal delivery of analgesics	210
<i>Intranasal morphine</i>	210
<i>Intranasal morphine derivatives</i>	211
<i>Intranasal fentanyl</i>	212
<i>Intranasal buprenorphine</i>	212
<i>Intranasal ketamine</i>	212
<i>Intranasal ketorolac</i>	213
<i>Nasal formulations for migraine</i>	213
Oral spray formulations for migraine	213
Delivery of analgesics by inhalation	213
Buccal transmucosal and sublingual delivery of analgesics	214
<i>Application for cancer pain</i>	214
<i>Application for non-cancer pain</i>	215
Pumps for drug delivery in pain	215
<i>Patient controlled analgesia</i>	216
<i>Postoperative pain pumps</i>	216
<i>Chronogesic (sufentanil) Pain Therapy System</i>	217
<i>PatchPump</i>	218
Intrathecal delivery of analgesics.....	218
Anatomical & physiological aspects of intrathecal drug delivery	218
Pharmacokinetics of intrathecal drug delivery	220
Epidural drugs	220
<i>Pharmacokinetics of analgesic drugs following epidural injection</i>	220
<i>Epidural glucocorticoids</i>	221
<i>Epidural etanercept</i>	221

<i>Epidural morphine</i>	221
Intrathecal drugs	221
<i>Intrathecal adenosine</i>	223
<i>Intrathecal baclofen</i>	223
<i>Intrathecal fadolmidine</i>	223
<i>Intrathecal lidocaine</i>	224
<i>Intrathecal magnesium sulfate</i>	224
<i>Intrathecal midazolam</i>	224
<i>Intrathecal opioids</i>	224
<i>Intrathecal neostigmine</i>	225
<i>Intrathecal octeoride</i>	226
<i>Intrathecal non-NMDA antagonists</i>	226
<i>Intrathecal prostaglandin antagonists</i>	226
<i>Intrathecal resiniferatoxin</i>	226
<i>Intrathecal ziconotide</i>	227
Combinations of intrathecal agents for relief of pain	227
Pumps for intrathecal delivery of analgesics	228
Complications of intrathecal delivery of analgesics	228
Concluding remarks on intrathecal delivery of analgesic agents	229
Intracerebroventricular morphine for pain	229
Development of drug delivery systems for pain therapy	230
Delivery of analgesics to the CNS across the blood brain barrier	230
Drug delivery systems in clinical trials	230
6. Drug Development for Pain.....	234
Introduction	234
Drugs in development for pain.....	234
Current research goals	235
The ideal analgesic.....	235
Pain R & D goals in the pharmaceutical industry	235
Drug targets in the spinal cord	236
Drug targets in the brain	236
Molecular targets for analgesic drugs.....	236
Activation of P2X7 receptors.....	236
Alfa2-adrenergic receptor agonists.....	237
Angiotensin II type 2 receptor	237
Anti-NGF strategies	237
Bradykinin antagonists	237
Cannabinoids.....	238
<i>Cannabinoid receptor agonists</i>	238
<i>Cannabidiol</i>	240
<i>Cannabinor</i>	241
<i>Nabilone</i>	241
Capsaicin and VR1 receptor-based analgesics	242
<i>Vanilloid (capsaicin) receptor antagonists</i>	242
<i>VR1 receptor agonists</i>	242
CCR2 receptor blockade.....	243
Cholecystokinin antagonists	243
Cholinergic receptor agonists.....	243
Conotoxins as analgesics	244
Corticotropin-releasing factor	245
FAAH inhibitors.....	245
<i>PF-3845</i>	246
<i>URB597</i>	246
FKBP51 as a target for treatment of chronic pain	246
Free radical scavengers as analgesics	247
<i>Superoxide dismutase mimetics</i>	247
GABA analogues	247
<i>Subtype-selective GABAergic drugs</i>	248
Glutamate receptor antagonists.....	248
<i>NMDA receptor modulation for neuropathic pain</i>	248
<i>Alternatives to direct blocking of NMDA receptors</i>	249
<i>Glycine antagonists</i>	249
<i>Metabotropic glutamate receptors</i>	249
Histogranin-like compounds for the management of pain	250
Ion channels as targets for analgesic drugs	250
<i>Acid-sensing ion channels as drug target</i>	250
<i>Calcium channel blockers</i>	251
<i>HCN1 channels as targets for propofol analogs for neuropathic pain</i>	251
<i>P2X ion channel receptor antagonists</i>	252
<i>Sodium channel modulation</i>	252

Mas-related GPCR agonists.....	253
Microsomal prostaglandin E synthase inhibitors	253
NAALADase inhibitors	254
Neuropeptide receptor antagonists for improving the efficacy of opioids.....	255
Neurotrophic factor-based pain therapeutics.....	255
<i>Glial cell line-derived neurotrophic factor</i>	255
<i>Nerve growth factor antagonists</i>	255
Newer COX inhibitors	256
<i>COX-3 inhibitors</i>	256
<i>Dual cyclooxygenase/lipoxygenase inhibitors</i>	256
Nicotinic acetylcholine receptors	256
<i>Mode of action of nACh/neural nicotinic receptor agonists</i>	257
<i>Potential of central nACh/neural nicotinic receptor agonists</i>	257
Nitric oxide-based analgesics.....	258
<i>Nitric oxide-releasing NSAIDs</i>	258
<i>Pharmacology of NO-SAIDs</i>	259
<i>COX-inhibiting nitric oxide donors</i>	259
<i>NO-donating structures to extend life cycle of existing analgesics</i>	260
<i>Nitric oxide mimetics</i>	260
<i>Neuronal nitric oxide synthase inhibitors</i>	260
Norepinephrine transporter inhibition	260
Opioid peptide receptors ligands	261
<i>Buprenorphine</i>	262
<i>Nociceptin</i>	262
<i>Opioids with unique receptor characteristics</i>	262
<i>Tapentadol</i>	263
Opioid analgesics acting outside the CNS	263
<i>Oliceridine</i>	263
<i>Opioid analgesics acting at peripheral receptors</i>	264
<i>Peripherally acting mu-opioid receptor agonists</i>	264
<i>Targeting of opioid peptide-containing immune cells</i>	264
<i>Advantages of peripherally selective opioid drugs</i>	265
Resolvins	265
Somatostatin analogs	265
Substance P and neurokinin receptor antagonists.....	265
Substance P-Saporin	266
Targeting prostanoid synthesis	267
Tetrodotoxin based analgesics	267
TRPV1 modulators.....	268
<i>TRPV1 antagonists</i>	268
<i>TRPV1 agonists</i>	269
<i>TRPV1-mediated entry of sodium channel blocker QX-314</i>	269
<i>TRPV1 receptors regulate longevity</i>	270
Tumor necrosis factor- α antagonists.....	270
Biological therapies for pain	271
Cell therapy for pain	271
Cells for delivery of antinociceptive molecules	272
Cell therapy for low back pain.....	272
Cell therapy for knee pain due to degenerative disorders	273
Cell therapy for peripheral neuropathic pain	273
Cell transplantation for relief of pain.....	273
<i>Transplantation of chromaffin cells</i>	273
<i>Transplantation of stem cells</i>	274
<i>Transplantation of astrocytes secreting enkephalin</i>	274
<i>Transplantation of cells for relief of neuropathic pain</i>	274
Concluding remarks on cell therapy for pain	275
Gene therapy for pain	276
Rationale of gene therapy for pain	276
<i>Gene therapy of peripheral neuropathy</i>	276
<i>Gene therapy targeted to neuroimmune component of chronic pain</i>	277
Methods of gene delivery for pain	277
Vectors for gene therapy of pain	278
<i>Vectors for endogenous analgesic production in cranial neuralgias</i>	278
Methods of gene delivery for pain	279
<i>Gene delivery by intrathecal route</i>	279
<i>Gene transfer to the dorsal nerve roots</i>	279
<i>Gene transfer by injections into the brain substance</i>	280
Antisense therapy for pain	280
RNAi-based approaches for pain therapy.....	281
Potential applications of gene therapy for management of pain	282
<i>Gene therapy for producing enkephalin to block pain signals</i>	282

Gene therapy for upregulation of BMP in backache	284
Gene therapy for targeting nuclear factor- κ B	284
Gene therapy for neuropathic pain	284
Zinc finger DNA-binding protein therapeutic for chronic pain	285
Concluding remarks about gene therapy for pain	285
Preclinical development of pain drugs	286
NGF-blocking antibody	286
Prostatic acid phosphatase as a novel analgesic	287
Preclinical development of drugs for neuropathic pain	287
5-HT receptor agonists	288
A-803467	288
α 9 α 10 antagonists	288
AM1241	289
Artemin/Neuroblastin	289
Capsazepine	290
Central nACh receptor agonists	290
CGP 35024	290
Cortistatin	291
Drugs that suppress glial activation	291
Erythropoietin	292
NO donating GABA-agonist drugs	292
Resiniferatoxin	292
Targeting tumor necrosis factor	293
Future targets for osteoarthritic pain	293
Pain drugs in clinical trials	293
Clinical trials of miscellaneous drugs for pain	294
Alvimopan	295
Asimadoline	296
EN3202	296
Oxytrex	296
Drugs in clinical trials for postsurgical pain	297
Bicifadine	298
DepoMorphine	298
Cox-2 inhibitors in clinical trials	299
Clinical trials of disease modifying therapies for arthritis	299
Drugs in clinical development for neuropathic pain	301
Adenosine A1 agonists for neuropathic pain	303
Ajulemic acid	304
AVP-923 (dextromethorphan + quinidine)	304
Botulinum toxin type A	304
Carisbamate	305
CNV1014802	305
D-amino acid oxidase inhibitors	305
Glyx-13	305
IP-751	306
Lacosamide	306
Oxcarbazepine	306
Perampanel	307
Ralfinamide	307
Retigabine	307
SB-509	307
TC-6499	308
Tebanicline	308
Tezampanel	308
Thalidomide	308
TRO19622	309
V3381 (indantadol)	309
XP-13512	309
Zonisamide	310
Drug discovery and development for migraine	310
Drugs in clinical development for treatment of migraine	311
Clinical development of preventive therapies for migraine	314
Drug development for visceral pain	314
7. Safety, Regulatory and Legal issues of pain management	316
Safety issues of analgesics	316
Adverse effects of analgesics	316
Gastrointestinal adverse effects of NSAIDs	316
Measures to reduce gastrointestinal adverse effects of NSAIDs	316
Cardiovascular adverse effects of COX-2 inhibitors	316
Adverse effects of opioids	317

<i>Addiction and development of tolerance</i>	317
<i>Chronic pain and opioid addiction</i>	318
<i>Abuse-deterrent opioid products</i>	319
<i>Problems and limitations of abuse-deterrent opioids</i>	320
<i>Complications of opioid abuse in the elderly</i>	321
<i>Hyperalgesia associated with opioids</i>	321
<i>Narcotic bowel syndrome</i>	322
<i>Opioid use disorder</i>	322
<i>Opioid withdrawal</i>	323
<i>Opioid-associated constipation</i>	323
<i>Respiratory depression</i>	323
Role of opioid prescribing patterns of physicians.....	323
Adverse effects of use of opioids in non-malignant pain.....	324
<i>Pharmacogenetics of adverse effects of codeine</i>	324
<i>PEGylated naloxol</i>	325
<i>Innovative approaches to modify opioid pharmacology</i>	325
Adverse effects of miscellaneous non-narcotic analgesics.....	325
<i>Adverse effects of immunosuppressants used for relief of pain</i>	325
<i>Adverse effects of acetaminophen</i>	326
<i>Hyponatremia as an adverse effect of tramadol</i>	326
Regulatory issues	326
Opioids.....	326
DEA and use of opioids for pain relief in terminal care.....	326
Cannabinoids.....	327
FDA and COX-2 inhibitors.....	327
Legal issues of COX-2 inhibitors	328
Regulatory aspects of opioid safety and abuse	328
Opioid misuse and regulatory agencies.....	328
FDA measures for safety of opioid use.....	329
Misuse of fentanyl.....	330
Regulation of extended release and long-acting opioids.....	330
Pain relief as a legal right	332
Pain relief and the WHO	332
8. Pain Markets	334
Introduction	334
Epidemiological basis of pain markets	334
Cancer.....	335
Neuropathic pain.....	335
Trigeminal neuralgia.....	335
Arthritis.....	335
Backache.....	335
Migraine.....	336
Multiple sclerosis.....	336
Irritable bowel syndrome.....	336
Chronic pelvic pain.....	336
Chronic pain due to traumatic brain injury.....	336
Postsurgical pain.....	337
Economics of pain	337
Pain as a driver of healthcare costs.....	337
Disability and financial loss through pain.....	338
Pain markets based on painful conditions	338
The cancer pain market.....	338
The arthritis pain market.....	339
Postsurgical pain market.....	339
The backache market.....	339
The headache market.....	340
Neuropathic pain market.....	340
Fibromyalgia market.....	341
Pain markets based on drugs	341
Opioids.....	341
Nonsteroidal antiinflammatory drugs.....	342
Transdermal pain therapeutics.....	342
Anesthesia.....	342
Antiepileptic drugs as analgesics.....	342
Other drugs.....	343
Hospital vs retail share of pain market.....	343
<i>Hospital versus retail opioid market</i>	343
Devices for pain.....	343
Pain markets according to geographical areas	343
Cost effectiveness of various approaches	344

Unfulfilled R&D needs in pain therapy	345
Under treatment of pain	345
Unfulfilled needs in drug development for chronic pain	345
Strategies for developing pain markets	346
Finding alternatives to intrathecal administration for chronic pain	346
Development of other applications of analgesic drugs	346
Partnership of patients, pharmacists and companies	347
Factors that may influence future pain markets	347
Drivers of pain markets	347
Public surveys as indicators of impact of pain on people	348
Effect of regulatory reviews on markets for pain products	348
Novel versus older therapies for pain	349
9. Future of Pain Therapeutics	350
Introduction	350
Advances in the understanding of pain	350
Pathogenesis of chronic pain	350
Role of glia in neuropathic pain	350
Molecular and neurobiological techniques	351
Improved understanding of cancer pain	352
Advances in drug discovery and development for pain	352
Novel targets for drug discovery for pain	352
<i>PTH2 receptor</i>	352
<i>Modulators of endogenous cannabinoids</i>	353
Application of new technologies to pain therapeutics	353
<i>Application of nanobiotechnology to pain therapeutics</i>	354
<i>Technologies for the manufacture of analgesics</i>	355
Future trends and needs in pain management	355
Pain management in future healthcare systems	356
Systems biology approach to pain	356
Personalized management of pain	357
Genetic factors in response to pain	358
Genetic mutations with loss of pain	359
Genetic mutations and painful conditions	359
Mechanism-specific management of pain	359
Pharmacogenomics and pharmacogenetics of pain	360
Personalized management of pain with commonly used analgesics	360
<i>Pharmacogenomics and pharmacogenetics of opioids</i>	360
<i>Pharmacogenetics of NSAIDs</i>	361
Preoperative testing to tailor postoperative analgesic requirements	361
Role of conditioned pain modulation in personalized management of pain	362
Signature of pain on brain imaging	362
Strategies for improving pain management	363
Research on pain in Europe	363
10. Companies Involved in Pain Therapeutics	366
Introduction	366
Profiles of companies	366
Collaborations	546
11. References	552

Tables

Table 1-1: Landmarks in the history of pain therapeutics	21
Table 1-2: Classification of pain	23
Table 1-3: Classification of neuropathic pain	25
Table 1-4: Classification of chronic cancer pain according to cause	27
Table 1-5: Percentage of patients with pain according to the type of cancer	28
Table 1-6: Key molecular elements of pain in the peripheral nervous system	51
Table 1-7: Key molecular elements of pain in the central nervous system	52
Table 2-1: IASP guidelines for the use of animals in pain studies	65
Table 2-2: Chronic pain as a manifestation of other diseases	66
Table 2-3: Recommendations for assessing patient satisfaction with pain management	72
Table 3-1: Classification of some currently used pain medications according to mechanism	78
Table 3-2: Drugs used for the treatment of pain	78
Table 3-3: Selective COX-2 inhibitors in clinical use for pain	80
Table 3-4: Antiepileptic drugs with analgesic effect	95
Table 4-1: Non-pharmacological approaches to management of pain	107

Table 4-2: Companies involved in neuromodulation therapy for pain	113
Table 4-3: Reasons for the inadequate management of acute pain.....	117
Table 4-4: Monoclonal antibodies as disease modifying therapies in rheumatoid arthritis	134
Table 4-5: Causes of chronic backache	136
Table 4-6: Management of chronic pelvic pain	139
Table 4-7: Management of pain in cancer	140
Table 4-8: Definitions of tolerance, physiological dependence, withdrawal and addiction.....	146
Table 4-9: A simplified classification of headache.....	146
Table 4-10: Various methods for the management of migraine.....	150
Table 4-11: Evidence-based level of choice of drugs for prophylaxis of migraine.....	155
Table 4-12: Management of neuropathic pain based on mechanism and diagnosis	160
Table 4-13: Management of central neuropathic pain	163
Table 4-14: Current management of peripheral diabetic neuropathy	166
Table 4-15: Treatment strategies for postherpetic neuralgia.....	168
Table 4-16: Management of complex regional pain syndrome.....	171
Table 4-17: Methods of treating phantom limb pain	173
Table 4-18: Treatment of chronic unexplained pain due to central sensitization	179
Table 4-19: Anti-itching therapies.....	180
Table 4-20: Suggested improvements in the management of pain	193
Table 5-1: A classification of drug delivery methods used in management of pain	198
Table 5-2: Selected marketed non-injection drug delivery systems for pain	203
Table 5-3: Approved drugs for spinal administration for pain.....	221
Table 5-4: Off-label intrathecal use of drugs for for pain	222
Table 5-5: Experimental studies of intrathecal administration of drugs for analgesia	222
Table 5-6: Intrathecal drugs for pain in clinical trials	222
Table 5-7: Comparison of pharmacokinetics of lipophilic with hydrophilic opioids	224
Table 5-8: Delivery systems for pain (other than intrathecal) in clinical development	231
Table 6-1: Classification of drugs in development for pain.....	234
Table 6-2: Preclinical studies on cannabinoid (CB2) receptor agonists as analgesics.....	239
Table 6-3: Cannabinoid receptor agonists in clinical development as analgesics.....	240
Table 6-4: NO-related therapies for pain.....	258
Table 6-5: Major opioids receptors and their ligands	261
Table 6-6: Strategies to counteract pain at various levels at periphery and in the CNS	267
Table 6-7: Types of TRPV1 antagonists.....	268
Table 6-8: TRPV1 antagonists in clinical trials.....	269
Table 6-9: Biological therapies for pain.....	271
Table 6-10: Experimental gene therapy approaches for relief of pain.....	277
Table 6-11: Selected preclinical approaches to pain therapy.....	286
Table 6-12: Selected preclinical drugs for neuropathic pain.....	287
Table 6-13: Selected clinical trials of miscellaneous drugs for pain	294
Table 6-14: Selected clinical trials of drugs for postsurgical pain.....	297
Table 6-15: COX-2 inhibitors in clinical development.....	299
Table 6-16: Disease modifying drugs for arthritis in clinical trials	299
Table 6-17: Clinical trials of drugs for neuropathic pain	301
Table 6-18: Selected drugs in clinical development for migraine	311
Table 6-19: Clinical trials of anti-CGRP monoclonal antibodies for migraine prevention	314
Table 6-20: Therapeutic targets for treating visceral pain	315
Table 7-1: Abuse-deterrent opioid products	320
Table 7-2: Diagnostic criteria for an opioid-use disorder	322
Table 8-1: Market values for various painful conditions 2016-2026	338
Table 8-2: Changes in market shares of drugs for neuropathic pain 2016-2026.....	340
Table 8-3: Markets for pain according to therapies 2016-2026	341
Table 8-4: Distribution of value of pain therapeutics in major markets 2016-2026	344
Table 8-5: Distribution of value of opioids in major pain markets 2016-2026.....	344
Table 8-6: Distribution of value of NSAIDs in major pain markets 2016-2026.....	344
Table 8-7: Strategies for developing pain markets	346
Table 9-1: P450 isoforms in the metabolism of drugs used in the management of pain.....	360
Table 10-1: Top companies in pain therapeutics	366
Table 10-2: Product pipeline of Adolor Corporation	373
Table 10-3: Selected collaborations in the area of pain management	546

Figures

Figure 1-1: Afferent pain pathways.....	30
Figure 1-2: Evolution of the gate control theory.....	32
Figure 1-3: The body self-neurometric.....	32
Figure 1-4: Various ligands and receptors on the peripheral terminals of nociceptive nerve fibers	52
Figure 1-5: Prostaglandin biosynthesis pathway	56
Figure 2-1: Biopsychosocial factors that interact and modulate the experience of pain.....	67
Figure 2-2: Pain intensity scales	68

Figure 3-1: Pathway of metabolism of codein	87
Figure 4-1: The WHO step ladder for pain	142
Figure 4-2: An algorithm for the acute management of migraine	152
Figure 4-3: Neuroimmune activation events leading to sensitization of CNS	159
Figure 4-4: An algorithm for the management of peripheral neuropathic pain.....	172
Figure 4-5: Algorithm for management of patients with chronic pain and depression.....	176
Figure 5-1: Powder Injection Systems	210
Figure 5-2: Penetration of CSF into spinal cord	219
Figure 5-3: Disposition of opioids after intrathecal administration	220
Figure 6-1: Attributes of the ideal analgesic	235
Figure 6-2: Nerve targeting drug delivery system for gene therapy of pain	283
Figure 8-1: Unfulfilled needs in the treatment for chronic pain.....	345
Figure 9-1: Impact of new technologies on pain therapeutics	354
Figure 9-2: Essential components of personalized management of pain	357
Figure 9-3: Genetic and non-genetic factors affecting efficacy and side effects of opioids.....	360